DeCODE Phase III Heart Attack Prevention Trial Takes Personalized Approach
This article was originally published in The Pink Sheet Daily
Executive Summary
Trial will use genetics to study a 5-lipoxygenase activating protein inhibitor in African-American patient population.
You may also be interested in...
DeCODE Suspends Phase III Heart Attack Prevention Trial
Manufacturing problem that caused dissolution decline in veliflapon tablets could take several months to resolve.
DeCODE Suspends Phase III Heart Attack Prevention Trial
Manufacturing problem that caused dissolution decline in veliflapon tablets could take several months to resolve.
NitroMed's BiDil Approved For Heart Failure In Self-Identified Black Patients
The hydralazine/isosorbide dinitrate combination is the first approval for a race-based indication. In its recent review of BiDil, an FDA advisory committee suggested race was serving as a surrogate for genomic markers. FDA suggests further study could expand BiDil's approval beyond self-identified black patients.